HOTH
Hoth Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.58 / 10
Netural
Fund flow evaluation is good (7.29/10), with positive small-scale inflows despite negative trends in larger blocks. Analyst coverage is limited but overwhelmingly bullish (Strong Buy 100%). The mismatch between positive fund flow and negative price trend highlights potential speculative interest, yet also underscores volatility and risk.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-04
InstitutionD. Boral Capital
Times predicted14
Historical Win Rate28.6%
What is the analyst consensus for HOTH?
- HOTH holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.58/10 (Netural).
